Matthew C Foster
Overview
Explore the profile of Matthew C Foster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan Y, Cho Y, Hirschey R, Piepmeier A, Bender C, Anderson R, et al.
Support Care Cancer
. 2024 Jul;
32(7):485.
PMID: 38960966
Purpose: To explore cancer-related cognitive impairment (CRCI) in older adults with acute myeloid leukemia (AML) receiving venetoclax in combination with hypomethylating agents or low-dose cytarabine chemotherapy. Methods: This study is...
2.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):209-218.
PMID: 37921062
A large-scale genomic analysis of patients with -mutated myeloid disease has not been performed to date. We reviewed comprehensive genomic profiling results from 6043 adults to characterize clinicopathologic features and...
3.
Cai S, Huang Y, Lance J, Mao H, Dunbar A, McNulty S, et al.
Blood Adv
. 2023 Oct;
8(2):429-440.
PMID: 37871309
Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy,...
4.
Johnson S, Haberberger J, Galeotti J, Ramkissoon L, Coombs C, Richardson D, et al.
Blood Cancer J
. 2023 Jun;
13(1):96.
PMID: 37365170
No abstract available.
5.
Duong V, Ruppert A, Mims A, Borate U, Stein E, Baer M, et al.
Cancer
. 2023 Apr;
129(15):2308-2320.
PMID: 37078412
Background: Patients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors...
6.
Jensen C, Montgomery N, Galeotti J, Foster M, Zeidner J
J Cell Mol Med
. 2022 Nov;
26(24):6079-6082.
PMID: 36444394
No abstract available.
7.
Saliba A, Kaufmann S, Stein E, Patel P, Baer M, Stock W, et al.
Blood Adv
. 2022 Oct;
7(11):2360-2363.
PMID: 36315007
No abstract available.
8.
Aldoss I, Yin J, Wall A, Mrozek K, Liedtke M, Claxton D, et al.
Blood Adv
. 2022 Oct;
7(2):196-204.
PMID: 36269846
Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However,...
9.
Jensen C, Heiling H, Beke K, Deal A, Bryant A, Coombs L, et al.
Haematologica
. 2022 Jul;
108(4):1006-1014.
PMID: 35861016
Time at home is a critically important outcome to adults with acute myeloid leukemia (AML) when selecting treatment; however, no study to date has adequately described the amount of time...
10.
Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani A, et al.
Blood Adv
. 2022 Jul;
6(14):4085-4092.
PMID: 35838753
In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic...